ReviewFrontiers in immunology2026
Atopic dermatitis and the gut-skin axis: a review from dysbiosis to novel targeted therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disorder with a complex pathogenesis involving genetic, immune, and environmental factors. Recent advances in the research on the gut-skin axis (GSA) have shed new light on the pathophysiology of AD, highlighting the critical role of gut microbiota dysbiosis in immune regulation and inflammatory responses. This review summarizes gut and skin microbial dysbiosis in AD and its impact on immune homeostasis, elaborates on molecular/cellular mechanisms by which gut-skin axis dysfunction drives AD inflammation, and focuses on targeted therapeutic strategies for gut-skin axis modulation. It outlines the latest research and clinical translation of interventions, including probiotics, prebiotics, postbiotics, dietary adjustments, fecal microbiota transplantation, and microbe/metabolite-targeted biologics, providing a theoretical basis for AD precision management and novel therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.